Pfizer STRIVEs For Staph Vaccine Broad Claim, But Future Development May Hinge On US FDA
Executive Summary
If Pfizer doesn't get regulatory clarity that Phase IIb/III STRIVE study data could support broad indication in elective orthopedic surgeries, company says it would have to reassess resources needed to continue current development program, with study termination a possible outcome.